Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

HHS Commits $884M to Swine Flu Vaccine Ingredients

By Pharmaceutical Processing | July 14, 2009

MARLEY SEAMAN AP Health Writer WASHINGTON (AP) — The U.S. Department of Health and Human Services plans to spend $884 million to buy two ingredients needed for a potential swine flu vaccine in case the 2009 version of the virus returns. Health and Human Services Secretary Kathleen Sebelius said the department is spending hundreds of millions to buy more of a swine flu antigen, or the part of a vaccine that creates an immune system response, and an adjuvant, which can boost that immune response. The spending is in addition to the $1 billion committed by Sebelius for the development and testing of a vaccine in May. The ingredients will be part of a stockpile of the vaccine in case a vaccination campaign becomes necessary, the department said. The Centers for Disease Control and Prevention says there have been more than 37,000 swine flu cases in the U.S., including 211 deaths, since the illness was identified this spring. Several drug developers are working on a vaccine for the 2009 swine flu, and the Department of Health and Human Services aims to have the vaccine ready by October, when the normal flu season starts. The orders will be added to existing contracts with some of the world’s largest drugmakers. The department said $690.1 million of the $884 million will go to Novartis AG, a Swiss company, which will deliver bulk vaccine antigen and bulk oil and water adjuvant. GlaxoSmithKline PLC of London will get $71.4 million for bulk oil and water adjuvant. Sanofi Pasteur, a part of French drugmaker Sanofi-Aventis, will receive $61.4 million for bulk vaccine antigen, and the MedImmune unit AstraZeneca PLC of Britain will be paid $61.2 million for bulk virus concentrate. The contracts date to 2004 as part of a strategy to fight a flu pandemic.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE